BackPanbela Therapeutics Overview

Panbela Therapeutics Net Tangible Assets

Track Panbela Therapeutics's net tangible assets ($-18M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-18.17M
631.70% YoYΔ $-15.69M vs prior year quarter

Peer average

Loading

Panbela Therapeutics Net Tangible Assets History

Loading

Panbela Therapeutics vs. peers: Net Tangible Assets Comparison

Loading

Panbela Therapeutics Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Panbela Therapeutics (PBLA) FAQ

Panbela Therapeutics's net tangible assets stands at $-18M as of September 2024. That compares with $-2.5M in the prior-year period — down 631.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Panbela Therapeutics reported $-18M in net tangible assets versus $-2.5M a year earlier — a 631.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-2.5M in the prior-year period — down 631.7% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Panbela Therapeutics's net tangible assets evolved across reporting periods, while the comparison chart places PBLA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Technology, net tangible assets is commonly used to spot outliers. Panbela Therapeutics's reading of $-18M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.